Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

Karolinska Institutet25 enrolled

Overview

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Human Immunodeficiency Virus Chronic Hepatitis C

Interventions

pegylated interferon-alpha (Pegasys)DRUG

Pegylated interferon-alpha 2a 180 micrograms s.c. weekly

ribavirin (COPEGUS)DRUG

ribavirin bid 800-1200 mg depending on HCV genotype and body weight

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-1 Hepatitis C coinfected adult patients * Hepatitis C treatment naive * Stable HIV-1 infection with or without cART * \> 300 CD4+ cell count Exclusion Criteria: * Decompensated liver disease * Ongoing depression * Ongoing drug abuse * Other contraindications for interferon or ribavirin treatment

Locations (1)

Karolinska University Hospital Solna

Stockholm, Sweden

Outcomes

Primary Outcomes

Sustained virological response

Time frame: 24 weeks end of treatment (EOT)

Secondary Outcomes

T-cell mediated immune responses

Time frame: baseline to 24 weeks EOT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.